NOVEL FUSED INDAN DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
    2.
    发明公开
    NOVEL FUSED INDAN DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF 失效
    NEUE KONDENSIERTE INDAN-DERIVATE UND IHRE PHARMAZEUTISCHVERTRÄGLICHENSALZE

    公开(公告)号:EP0713870A4

    公开(公告)日:1996-12-18

    申请号:EP95918733

    申请日:1995-05-18

    摘要: A fused indan derivative represented by general formula (1), a pharmaceutically acceptable salt thereof, and an antitumor drug, wherein ring A represents an optionally substituted benzene or naphtalene ring, or a benzene ring having a lower alkylenedioxy group; ring B represents a benzene ring which may be substituted or has a lower alkylenedioxy group; Y represents -N=CR- or -CR=N-; R represents -NR1R2, -OR3 or an optionally substituted nitrogenous heterocyclic group; R1 and R2 are the same or different from each other and each represents hydrogen, phenyl, an optionally substituted nitrogenous heterocyclic group, or a lower alkyl group which may be substituted by at least one substituent selected from the group consisting of optionally substituted amino, lower alkoxy, phenyl, a nitrogenous heterocyclic group, an amine oxide group substituted by lower alkyl, and hydroxy; and R3 represents lower alkyl which may be substituted by substituted amino, provided the case where R represents an optionally substituted nitrogenous heterocyclic group and rings A and B represent each an unsubstituted benzene ring, is excluded.

    摘要翻译: 由通式(1)表示的稠合茚满衍生物,其药学上可接受的盐和抗肿瘤药物,其中环A表示任选取代的苯或萘环或具有低级亚烷基二氧基的苯环; 环B表示可被取代或具有低级亚烷基二氧基的苯环; Y代表-N = CR-或-CR = N-; R代表-NR 1 R 2,-OR 3或任选取代的含氮杂环基团; R1和R2彼此相同或不同且各自代表氢,苯基,任选取代的含氮杂环基团或可被至少一个选自以下的取代基取代的低级烷基:任选取代的氨基,低级 烷氧基,苯基,含氮杂环基团,被低级烷基取代的氧化胺基团和羟基; 并且R3代表可以被取代的氨基取代的低级烷基,条件是其中R代表任选取代的含氮杂环基并且环A和B各自代表未取代的苯环的情况被排除。